Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Tanaka H, Hasegawa Y, Fujita Y, Nakamura A, Kikuchi E, Kawai Y, Harada T, Watanabe N, Yokouchi H, Usui K, Saito R, Watanabe H, Masuda T, Fukuhara T, Kudo K, Honda R, Oizimi S, Maemondo M, Inoue A, Morikawa N.
Tanaka H, et al. Among authors: watanabe h, watanabe n.
Thorac Cancer. 2021 Jul;12(14):2113-2121. doi: 10.1111/1759-7714.14048. Epub 2021 Jun 2.
Thorac Cancer. 2021.
PMID: 34076966
Free PMC article.
Clinical Trial.